Active lupus in Argentina: Results of a multicenter and national registry
- 8 November 2023
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 32 (13) , 1555-1560
Abstract
Objective: To evaluate the association between patients’ characteristics and disease activity in an Argentine lupus registry. Methods: Cross-sectional study. Disease activity was stratified into: Remission off-treatment: SLEDAI = 0, without prednisone and immunosuppressive drugs. Low disease activity Toronto Cohort (LDA-TC): SLEDAI ≤2, without prednisone or immunosuppressive drugs. Modified lupus low disease activity (mLLDAS): SLEDAI score of ≤4, with no activity in major organ systems and no new features, prednisone of ≤10 mg/day and/or immunosuppressive drugs (maintenance dose) and Active disease: SLEDAI score of >4 and prednisone >10 mg/day and immunosuppressive drugs. A descriptive analysis and logistic regression model were performed. Results: A total of 1346 patients were included. Of them, 1.6% achieved remission off steroids, 0.8% LDA-TC, 12.1% mLLDAS and the remaining 85.4% had active disease. Active disease was associated with younger age ( p ≤ 0.001), a shorter time to diagnosis ( p ≤ 0.001), higher frequency of hospitalizations ( p ≤ 0.001), seizures ( p = 0.022), serosal disease ( p ≤ 0.001), nephritis ( p ≤ 0.001), higher SDI ( p ≤ 0.001), greater use of immunosuppressive therapies and higher doses of prednisone compared to those on mLLDAS. In the multivariable analysis, the variables associated with active disease were the presence of pleuritis (OR 2.1, 95% CI 1.2–3.9; p = 0.007), persistent proteinuria (OR 2.5, 95% CI 1.2–5.5; p ≤ 0.011), nephritis (OR 2.5, 95% CI 1.2–5.6; p = .018) and hospitalizations (OR 8.9, 95% CI 5.3–16.0; p ≤ 0.001) whereas age at entry into the registry was negatively associated with it (OR 0.9, 95% CI 0.9–1.0; p = 0.029). Conclusion: Active disease was associated with shorter time to diagnosis, worse outcomes (SDI and hospitalizations) and renal, neurological and serosal disease.Keywords
This publication has 14 references indexed in Scilit:
- 2019 update of the EULAR recommendations for the management of systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2019
- Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American CohortThe Journal of Rheumatology, 2019
- First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)Annals of the Rheumatic Diseases, 2018
- Treat to target, remission and low disease activity in SLEBest Practice & Research Clinical Rheumatology, 2017
- Prolonged remission in Caucasian patients with SLE: prevalence and outcomesAnnals of the Rheumatic Diseases, 2015
- Prolonged Clinical Remission in Patients with Systemic Lupus ErythematosusThe Journal of Rheumatology, 2014
- Optimizing outcome in SLE: treating-to-target and definition of treatment goalsAutoimmunity Reviews, 2014
- Treat-to-target in systemic lupus erythematosus: recommendations from an international task forceAnnals of the Rheumatic Diseases, 2014
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992